FDA Approves Johnson & Johnson’s DARZALEX FASPRO as First Treatment for High-Risk Smoldering Multiple Myeloma Read more
UCB Secures FDA Approval for KYGEVVI, the First-Ever Treatment for Ultra-Rare TK2 Deficiency Read more
FDA Expands Approval of Merck’s WINREVAIR for Pulmonary Arterial Hypertension Following Strong Phase 3 Results Read more
GSK Acquires Exclusive Rights to Syndivia’s Next-Generation ADC for Advanced Prostate Cancer Read more